Introduction
============

Vancomycin-resistant *Enterococci* (VRE) strains were reported first in United Kingdom and France in 1986, and after that in the United States ([@B1]). At present, these organisms are significantly isolated in hospitals around the world, especially in patients with hemato-oncological diseases and hospitalized in intensive care units ([@B2]). Currently, nine types of vancomycin-resistance have been described in *Enterococci*, eight of these types correspond to acquired resistance, i.e., *vanA, vanB, vanD, vanE, vanG, vanL, vanM* and *vanN*; one type-*VanC*-have been identified in species of *Enterococcus gallinarum* and *E. casseliflavus--E. flavescens* intrinsically resistant to low levels of vancomycin but remain susceptible to teicoplanin and have been found in human intestinal tract ([@B3], [@B4]).

Among vancomycin-resistance genotypes in *Enterococci*, *vanA* and *vanB* possess greatest clinical significance ([@B5]). The *vanA* genotype is the most commonly genotype in VRE worldwide, and is associated with the transfer of a considerable amount of vancomycin resistance from *Enterococci*, particularly, vancomycin-resistant *E. faecium (*VREF*)* to *Staphylococcus aureus* ([@B1], [@B6]). The *vanA*-type genes play an important role in inducing resistance against both teicoplanin and vancomycin, while the level of resistance to vancomycin in strains sheltering *vanB*-type genes are not constant but somewhat variable (MICs, 4 to 1,024 mg/l). Moreover, remain susceptible to teicoplanin (MICs, ≤ 2 mg/l) in vitro ([@B4]). The low-level resistance against such antibiotics as vancomycin vancomycin (vancomycin \[MIC\], 64--128 mg/ml) and susceptibility or intermediate resistance to teicoplanin (teicoplanin MIC, 8--16 mg/ml) is one of the main features of the *vanD* phenotype ([@B7]).

Although these organisms lacking strong virulent factors, but *enterococcal* infection is intricated by the intrinsic resistant / tolerant to many important antimicrobial agents including cephalosporin, lincomycin, cotrimoxazole, and low levels of penicillin and aminoglycosides, and as well as by the ability to acquire resistance to penicillins, chloramphenicol, tetracyclines, aminoglycosides (high-level) and vancomycin either by mutation, or by acquisition of plasmids or transposons ([@B8], [@B9]). Thus, the incidence of antimicrobial resistant *Enterococci*, especially VRE is a persisting clinical problem in public health care facilities in all geographical areas ([@B9]). Cytolysin (*Cyl*), gelatinase (*GelE*) and aggregation substance (*Agg*) are virulence factors identified in *E. faecalis* that can influence the relationship between parasite and host, on other hand, *esp* and *hyl* have been found in both *E. faecalis* and *E. faecium* ([@B10], [@B11]). "These virulence factors may causes increasing persistence of *enterococci* in the nosocomial environment, and consequently inter and intra-hospitals dissemination" ([@B10]).

Regarding the virulence determinants in clinical isolates of *Enterococci* that may result in promoting emergence of infections and persistence of this organism in nosocomial settings and consequently leads to increased resistance ([@B5]), this study was undertaken to determine the antimicrobial susceptibility patterns and virulence factors including *esp* (*enterococcal* surface protein), *asa~1~* (aggregation substance), *gelE* (*gelatinase*), *hyl* (*hyaluronidase*) in clinical isolates of *E. faecalis* and *E. faecium*.

Materials and Methods
=====================

Identification of enterococcal isolates
---------------------------------------

One hundred and seventy-five *E. faecalis* and sixty-seven *E. faecium* isolates were collected from different clinical specimens submitted in three teaching hospitals located in Hamedan/ western Iran, from Dec 2012 to May 2014. The origins of isolates were as follows: urine 200 (82.6%), tracheal 17 (7%), blood 8 (3.3%), wound 6 (2.5%), abscess and lower respiratory tract 6 (2.5%), and body fluids 5 (2.1%). *Enterococcus* genus were identified using routine microbiological methods ([@B9]) then, PCR targeting D-alanine- D-alanine ligases specific for *E. faecalis* (*ddl E. faecalis*) and *E. faecium* (*ddl E. faecium*) was used to confirm phenotypic speciation ([@B12]).

DNA extraction
--------------

*Enterococci* chromosomal *DNA* was extracted by boiling method. Briefly, 3--5 clones of overnight bacterial culture was suspended in 500 μl of sterile distilled water, boiled for 10--15 min, and then centrifuging at 14000 g for 5 min to pellet cell debris ([@B13]).

Detection of E. faecalis and E. faecium species by PCR
------------------------------------------------------

PCR reactions of *ddl E.faecalis* and *ddl E.faecium* genes were performed with previously designed primers ([Table 1](#T1){ref-type="table"}), with some modification on Kariyama's protocol ([@B12]) using Eppendorf and Biorad thermocycler (ASTEC Co., Japan) in a final volume of 20 μl containing 2 μl template DNA, 1 μl of each primer, 10 μl of Master Mix, 6 μl of sterile distilled water. The optimum conditions of PCR for both genes were as follows: an initial denaturation at 95 °C for 5 min, followed by amplification by 30 cycles of denaturation at 95 °C for 30 sec, annealing at 52.5 °C for 30 sec and elongation at 72 °C for 1 min, and a final extension at 72 °C for 10 min. The *E. faecalis* ATCC 29212 and *E. faecium* BM4147 were used as quality control strains.

###### 

Primers used in this study

  --------------------------------------------------------------------------------------------------------
  **Gene targets**    **Primer sequences (5′ to 3′)**   **amplicon / product size (bp)**   **Reference**
  ------------------- --------------------------------- ---------------------------------- ---------------
  *asa~1~*            F: GCACGCTATTACGAACTATGA\         375                                13
                      R: TAAGAAAGAACATCACCACGA                                             

  *hyl*               F: ACAGAAGAGCTGCAGGAAATG\         276                                13
                      R: GACTGACGTCCAAGTTTCCAA                                             

  *esp*               F: AGATTTCATCTTTGATTCTTGG\        510                                13
                      R: AATTGATTCTTTAGCATCTGG                                             

  *ddl E. faecalis*   F: ATCAAGTACAGTTAGTCTTTATTAG\     941                                12
                      R: ACGATTCAAAGCTAACTGAATCAGT                                         

  *ddl E. faecium*    F: TTGAGGCAGACCAGATTGACG\         658                                12
                      R: TATGACAGCGACTCCGATTCC                                             

  *vanA*              F: GGGAAAACGACAATTGC\             732                                12
                      R: GTACAATGCGGCCGTTA                                                 

  *vanB*              F: ATGGGAAGCCGATAGTC\             635                                12
                      R: GATTTCGTTCCTCGACC                                                 

  *vanD*              F: TGTGGGATGCGATATTCAA\           500                                14
                      R: TGCAGCCAAGTATCCGGTAA                                              
  --------------------------------------------------------------------------------------------------------

Antibiotic susceptibility testing
---------------------------------

Antibiotic susceptibility testing of 175 *E. faecalis* strains and 67 *E. faecium* strains was performed using Kirby-Bauer disk diffusion method on Muller-Hinton agar in according to the Clinical and Laboratory Standards Institute (CLSI) guidelines ([@B14]). Antimicrobial agents used in this study were included: vancomycin (30 μg), teicoplanin (30 μg), tetracycline (30 μg), erythromycin (15 μg), norfloxacin (10 μg), ciprofloxacin (5 μg), nitrofurantoin (300 μg), quinopristin-dalfopristin \[synercid (15 μg)\] (Mast co., UK), chloramphenicol (30 μg), linezolid (30 μg), gentamicin (10 μg), and ampicillin (10 μg) (HiMedia Mumbai Co., India).

Determination of minimum inhibitory concentration (MIC) of the glycopeptide antibiotics i.e. vancomycin and teicoplanin (Sigma-Aldrich, Poole, Co., UK) for *E. faecalis* and *E. faecium* isolates was done using microdilution broth method and Cation Adjustment Muller Hinton Broth (CAMHB) medium according to the CLSI guidelines ([@B14]). The *E. faecalis* ATCC 29212 (Vancomycin sensitive)*, E. faecalis* ATCC 51299 (*vanB* positive), *E. faecalis* E206 (*vanA* positive) were used as quality control strains for performing antimicrobial tests.

Detection of van determinants
-----------------------------

Isolates with a vancomycin and teicoplanin Minimum Inhibitory Concentration (MIC) of 2 μg/ml were analyzed by PCR for the presence of the genes encoding the vancomycin-resistance determinants *vanA*, *vanB*, *vanD* using specific primers ([Table 1](#T1){ref-type="table"}). The PCR reaction was performed in a volume of 20 μl and contained: 2 μl template *DNA*, 1 μl of each primer, 10 μl of Master Mix, 6 μl of sterile distilled water on a Eppendorf and Biorad thermocycler (ASTEC Co., Japan) with an initial denaturation at 94 °C for 3 min, 30 cycles of amplification (denaturation at 94 °C for 1 min, annealing at 54 °C for 1 min, and extension at 72 °C for 1 min), and a final extension at 72 °C for 7 min ([@B12]).

Detection of virulence genes esp, hyl, and asa ~1~ by PCR
---------------------------------------------------------

Identify of three virulence determinants in all *E. faecalis* and *E. faecium* isolates was performed by Multiplex PCR *(esp, asa ~1~)* and single PCR *(hyl)* using specific primers for each gene ([Table 1](#T1){ref-type="table"}), with some modification on Vankerckhoven's protocol. the first 25 μl of PCR mixture contained 3 μl of template *DNA* (1μl of plasmid *DNA*, 2 μl of chromosome *DNA*), 1μl of each primer for genes *esp* and *asa ~1~*, 12.5 μl of Master Mix, and 5.5 μl of sterile distilled water; the second 20 μl PCR mixture contained 2 μl of template *DNA*, 1 μl of each primer for *hyl*, 10 μl of Master Mix, and 6 μl of sterile distilled water. The PCR conditions included a pre-denaturation step at 95 °C for 10 min, followed by 30 cycles of 1 min at 94 °C, 1 min at 56 °C and 1 min at 72 °C. A final extension step was performed at 72 °C for 10 min ([@B13]). The *E. faecalis* ATCC 29212 (*asa1* positive), *E. faecium* C68 (*hyl* and *esp* positive) were used as quality control strains.

Statistical analysis
--------------------

Data were analyzed statistically using Chi-Square test and difference was considered significant at *P*\<0.05 by SPSS software version 19 (Chicago, IL, USA).

Results
=======

Enterococci isolates
--------------------

Of 280 *enterococcal* isolates, 190 (67.8%) isolates were identified as *E. faecalis*, 75 (26.8%) as *E. faecium* and 15 (5.4%) as *Enterococcus* spp., using biochemical methods. Overall, 175 (62.5%) *E. faecalis* strains (5.62%) and 67 *E. faecium* strains (24%) were confirmed by the PCR method. A total of 38 strains (13.5%) have remained to the *Enterococcus* genus. The most of isolates 95 (39.3%) were collected from internal ward, followed by Outpatient ward with 72 (29.8%), Nephrology 26 (10.7%), ICU 22 (9.1%), Emergency 21 (8.7%), Burn 3 (1.2%), and Surgeryandcardiaccare 3 (1.2%).

Antimicrobial susceptibility testing
------------------------------------

Resistance to the majority antibiotics except for chloramphenicol, tetracycline, and quinopristin-dalfopristin was higher in *E. faecium* isolates than *E. faecalis* isolates. However, they showed good rate of sensitivity to linezolid (100%), nitrofurantoin and chloramphenicol (74.6%). All isolates of *E. faecalis* were susceptible to nitrofurantoin. None of the *Enterococcus* isolates was resistant to linezolid. The susceptibility patterns of *E. faecium* and *E. faecalis* to antibiotics are presented in [Table 2](#T2){ref-type="table"}.

###### 

Antibiotic resistance behavior of *Enterococci* isolates with disk diffusion

  **Antimicrobial agent**   **Percent of *E. faecalis* isolates (n=175)**   **Percent of *E. faecium* isolates (n=67)**   **Total**                                      
  ------------------------- ----------------------------------------------- --------------------------------------------- ----------- ------ ------ ------ ------ ------ ------
  Vancomycin                95                                              0                                             5           24     0      76     75.2   0      24.8
  Teicoplanin               95                                              0                                             5           27     0      73     76     0      24
  Ampicillin                96.6                                            0                                             3.4         39.3   0      62.7   80.2   0      19.8
  Tetracycline              9.7                                             2.3                                           88          21     6      73     12.8   3.3    83.9
  Ciprofloxacin             36.6                                            24                                            39.4        0      19.4   80.6   26.5   22.7   50.8
  Norfloxacin               63                                              4                                             33          0      16.4   83.6   45.5   7.4    47.1
  Erythromycin              26.3                                            11.4                                          62.3        0      13.4   86.6   19     12     69
  Synercid                  4.6                                             0                                             95.4        24     6      70     10     1.6    88.4
  Chloramphenicol           54.3                                            13.1                                          32.6        74.6   15     10.4   60     13.6   26.4
  Gentamicin                56                                              8                                             36          1.5    6      92.5   41     734    51.6
  Nitrofurantoin            100                                             0                                             0           74.6   0      25.4   93     0      7
  Linezolid                 100                                             0                                             0           100    0      0      100    0      0

Of 175 isolates of *E. faecalis*, resistance of 9 and sensitivity of 166 isolates to vancomycin and teicoplanin were confirmed by microdilution broth method.

Of 67 isolates of *E. faecium*, 51 strains were resistant to vancomycin by disk diffusion method, but resistance of 49 strains to vancomycin was confirmed by Microdilution Broth. Two strains of *E. faecium* determined as resistant strains by disk diffusion using Microdilution Broth were identified as intermediate strains, corresponded with identification *vanB* gene in these two strains ([Table 3](#T3){ref-type="table"}).

###### 

Results of MIC for glycopeptides antibiotics of vancomycin and teicoplanin in *E. faecium* and *E. faecalis* strains

  **Antimicrobial agent**   **E. faecium**   **E. faecalis**                                                   
  ------------------------- ---------------- ----------------- ------- ------- ------- ------- ------- ------- -------
  **Sensitivity Status**    **S**            **R**             **S**   **I**   **R**   **S**   **R**   **S**   **R**
  **MIC (μg/ml)**           8≤               32≥               4≤      8--16   32≥     8≤      32≥     4≤      32≥
  **Number**                18               49                16      2       49      166     6       166     9
  **Percent (%)**           26.9             73.1              24      3       73      95      5       95      5

Analysis of vanA-vanB-vanD types vancomycin resistance genes
------------------------------------------------------------

All VRE*~fs~* and 49 of VRE*~fm~* strains (96.7%) had high-level resistance to vancomycin and teicoplanin carried the *vanA* gene. Two VRE*~fm~* isolates (3.3%) had moderate-Level resistant to vancomycin with MIC=8 μg /ml and were insensitive to teicoplanin, carried the *vanB* gene, *vanD* gene was identified in none of VRE strain.

Prevalence of virulence genes in E. faecalis and E. faecium strains
-------------------------------------------------------------------

Among the *E. faecalis* strains, the *asa~1~* gene was the most prevalent factor, followed by the *esp* and *hyl* genes; additionally, in *E. faecium* strains, the *asa~1~* gene was the highest prevalence and *hyl* gene has the lowest frequency, followed by the *esp* gene.

Results of statistical analysis
-------------------------------

Using SPSS software, there were significant correlations between the disk diffusion agar and broth microdilution methods for vancomycin and teicoplanin antibiotics (*P*≤0.001); and between PCR and MIC ~Vanco~ and MIC ~Teico~ results (*P*≤0.001) in strains of *E. faecalis* and *E. faecium.*

Discussion
==========

In the present study, of 280 *enterococcal* isolates, 175 isolates were identified as *E. faecalis*, 67 as *E. faecium* and 38 *as Enterococcus* spp. The prevalence of *E. faecalis* strains were reported 76% and 55.5% respectively ([@B15], [@B9]). In Iran, the prevalence of *E*. *faecalis* and *E. faecium* strains were reported 77.5% and 22.5%, 70.4% and 18.5%, 85.3% and 10.8%, 28% and 71%, respectively ([@B8], [@B16]--[@B18]). VRE strains are resistant to different classes of antibiotics simultaneously. Rising high-level resistance to penicillin, ampicillin and aminoglycosides has been demonstrated in recent years, especially in vancomycin-resistant *E. faecium* strains. Multidrug-resistant strains of *Enterococci*, especially *E*. *faecalis* and *E. faecium* are serious problems in treatment patients with enterococcal infections due to improper use of antibiotics ([@B19]). In the current study, 85% of strains of *E. faecalis* and all *E. faecium* strains had multidrug resistance, but strains of vancomycin-resistant compared to susceptible strains were resistant to greater number of antibiotic classes.

In the current study, the prevalence of vancomycin resistance was found 24%, which was consistent with some previous ([@B9], [@B20]). The prevalence of vancomycin resistance in *Enterococcus* strains were reported 23.3% and 29%, respectively. Similar studies in Iran reported the prevalence of vancomycin resistance in *Enterococcus* strains as 24.10%, 16.9%, 14.6%, 25%, 22%, respectively (16, 18, 21--23). According to typing results of genotypes for resistance to vancomycin, *vanA*-type was the most common genotype seen among VRE strains obtained in Hamadan and *vanB* is the second. Majority of the VRE isolates (96.8%) have the *vanA* gene, 3.3% of VRE isolates with vanC, and *vanB* genotype was identified in any VRE strains ([@B24]). All VRE*~fm~* strains (100%) carrying the *vanA* gene; but *vanB-C-D-E-G* genotypes were not reported ([@B25]). The frequency of genes *vanA* and *vanB* among VRE strains were identified 85% and 15%, 62.5% and 37.5%, 69.23% and 15.38% respectively ([@B16]). Increase in the prevalence of VRE, especially *E. faecium*, in different countries has been attributed mainly to the incidence and diffusion of *vanA* and *vanB* positive VRE, which exhibited some virulence factors such as Esp (*esp*), cytolysin (*cyl*), and hyaluronidase (*hyl*). The extracellular surface protein *(esp)*, encoded by the chromosomal *esp* gene, found on pathogenicity island in multidrug-resistant pathogenic lineages of both *E. faecalis* and *E. faecium* strains. Esp is a cell wall-associated protein which contribute to the colonization and persistence of *E. faecalis* strains in ascending infections of the urinary tract. In addition, Esp may participate in biofilm formation, and may also be involved in antimicrobial resistance ([@B26], [@B27]). Blood and wound infections caused by *Enterococci* strains are mediated by Esp protein ([@B28]). In a study, the gene *esp* was detected only in *E. faecalis* strains ([@B29]). However, incidence of the gene *esp* in clinical *E. faecium* are increasing compared to clinical *E. faecalis* isolates ([@B30]).

In the present study, prevalence of the genes *esp* and *hyl* were significantly higher among ampicillin-resistant VRE*~fm~* isolates (53.7%, 37.3%) compared to ampicillin-susceptible VRE*~fm~* isolates (19.4%, 22.4%). This finding is in accordance with the reported results of other related studies ([@B32]--[@B34]). In our study, the frequency of the gene *asa~1~*, (which encodes aggregation substance) among *E. faecalis* was as high as 97 percent and among *E. faecium* strains was as high as 100 percent. This gene has a high incidence in *E. faecalis*, as well. Results of studies on clinical *E. faecium* isolates are contradictory. Previous studies detected this virulence factor among 5%, 65% of VRE*~fm~* and 2.7%, 60% of VRE*~fs~* strains ([@B26], [@B35]). S Jahangiri et al. ([@B11]) did not found gene *asa~1~* in either 49 of VRE*~fm~* strains or 17 of VSE*~fm~* strains.

Hyaluronidase, coded by the chromosomal gene *hyl*, is a degradative enzyme associated with tissue damage that influence on the hyaluronic acid (hyaluronate, HA) ([@B33]). We found the *hyl* gene among 49.3% of VRE*~fm~* isolates and 22.4% of VSE*~fm~* isolates, which is in accordance to Rice et al. results ([@B36]), who detected the *hyl* gene among 71% of the United Kingdom VRE*~fm~* isolates; but it was in contrast to another study ([@B11]), who detected gene *hyl* among 80% of VSE*~fm~* isolates and in 28.5% of VRE*~fm~* isolates. Most of *esp*-positive isolates were resistant to more than 3 antibiotics ([@B11], [@B37]). Laud B et al. ([@B38]) demonstrated that the strong correlation between the carriage of gene *esp* and antimicrobial resistance could be due to the higher conjugation frequencies in strains carrying the *esp* gene than strains lacking this gene. *E. faecium* strains carrying the gene *esp* were resistant to more than 90% of the antibiotics tested and 64% of *E. faecium* strains were resistant to vancomycin ([@B5]).

Considering these results, the gene *esp* facilitates *E. faecium* isolates ability to acquire antibiotic resistance genes. The expression level of gene *esp* depending on growth conditions constantly vary between strains of *E. faecium* and is associated with initial connection and biofilm formation ([@B39]).

Conclusion
==========

Due to increasing resistance rate of *Enterococci* to most common antibiotics, applying the preventive and control measures are required.
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